Molecular and cellular pathology of intrinsic brain tumours

Cancer and Metastasis Reviews

Volumn 16, Issue 1-2, 1997, Pages 155-177

  Merzak, Abderrahim ^a   Pilkington, Geoffrey J ^b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

biology; brain; glioma; molecular; pathology; tumour

Indexed keywords

BRAIN TUMOR; GLIOMA; HUMAN; MOLECULAR GENETICS; PRIORITY JOURNAL; REVIEW;

BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; GLIOMA; HUMANS; INCIDENCE;

EID: 0030977964     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005760726850     Document Type: Review

References (255)

1. Davis DL, Ahlbom A, Hoel D, Percy C: Is brain cancer mortality increasing in industrial countries? Am J Indust Med 19: 421-431, 1991
2. Modan B, Wagener DK, Feldman JJ, Rosenberg HM, Feinleib M: Increased mortality from brain tumors: a combined outcome of diagnostic technology and change in attitude toward the elderly. Am J Epidemiol 135: 1349-1357, 1992
3. Wrensch M, Bondy ML, Wiencke J, Yost M: Environmental risk factors for primary malignant brain tumors: a review J Neuro-oncology 17: 47-64, 1993
4. Pilkington GJ: The biology pathogenesis and spread of malignant glioma. Strahlentherapie und Onkologie 165: 235-238, 1989
5. Bernstein JJ, Woodard CA: Glioblastoma cells do not intravasate into blood vessels. Neurosurgery 36: 124-32, 1995
6. Martin K, Akinwunmi J, Rooprai HK, Kennedy AJ, Linke A, Ognjenovic N, Pilkington GJ: Nonexpression of CD15 by neoplastic glia: a barrier to metastasis? Anticancer Res 15: 1159-1166, 1995
7. Weller RO, Ellison DW: Pathology of brain tumours: the current state of diagnostic practice. Neuropath Appl Neurobiol 22: 000-000, 1996 (in press)
8. Kleihues P, Burger PC, Scheithauer BW: Histological typing of tumors of the central nervous system. 2nd Edn Berlin: Springer-Verlag, 1993
9. Kernohan JW, Habon RF, Svien HJ, Adson AW: A simplified classification of gliomas. Proc Mayo Clin 24: 71-75, 1949
10. Daumas-Duport C, Scheithauer B, O'Fallon J et al.: Grading of astrocytomas. Cancer 62: 2152-2165, 1988
11. Pilkington GJ, Lantos PL: Biological markers for tumours of the brain. In: Symon L et al. (ed.) Advances and Technical Standards in Neurosurgery, Vol 21. Springer-Verlag Wien. New York, Chapter 1 pp 2-41, 1994
12. Raff MC, Miller RH, Noble M: A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 303: 390-396, 1983
13. Daumas-Duport C, Scheithauer BW, Chodkiewicz J-P, Laws Jr ER, Vedrenne C: Dysembryoplastic neuroepithelial tumour: a surgically curable tumor of young patients with intractable partial seizures. Neurosurgery 23: 545-556, 1988
14. Lane DP: p53, guardian of the genome. Nature 358: 15-16, 1992
15. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993
16. Owen-Schauh LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, Radinsky R: Wild type human p53 a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15: 3032-3040, 1995
17. Jayaram L, Prives C: Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81: 1021-1029, 1995
18. Prives C: How loops, sheets, and helixes help us understand p53. Cell 78: 534-546, 1994
19. Wu JK, Ye Z, Darras BT: Frequency of p53 tumor suppressor gene mutations in human primary brain tumors. Neurosurgery 33: 824-830, 1993
20. Von Deimling A, Eibl RH, Ohgaki H, Louis DN, von Ammon K, Petersen I, Kleihues P, Chung RY, Wiestler OD, Seizinger BR: p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 52: 2987-2990, 1992
21. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355: 846-847, 1992
22. Del Arco A, Garcia J, Arribas C, Barrio R, Blazquez MG, Izquierdo JM, Izquierdo M: Timing of p53 mutations during astrocytoma tumorigenesis. Hum Mol Genet 2: 1687-1690, 1993
23. Litofsky NS, Hinton D, Raffel C: The lack of a role for p53 in astrocytomas in pediatric patients. Neurosurgery 34: 967-972, 1994
24. Felix CA, Slave I, Dunn M, Strauss EA, Phillips PC, Rorke LB, Sutton L, Bunin GR, Biegel JA: p53 gene mutations in pediatric brain tumors. Med Pediatr Oncol 25: 431-436, 1995
25. Merzak A, Raynal S, Rogers JP, Lawrence D, Pilkington GJ: Human wild type p53 inhibits cell proliferation and elicits dramatic morphological changes in human glioma cell lines in vitro. J Neurol Sci 127: 125-133, 1994
26. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, Nister M: Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of automne and paracrine loops. Cancer Res 52: 3213-3219, 1992
27. Fleming TR Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali-IU: Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52: 4550-4553, 1992
28. Hermanson M, Funa K, Koopmann J, Maintz D, Waha A, Westermark B, Heldin CH, Wiestler OD, Louis DN, von-Deimling A, Nister M: Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res 56: 164-171, 1996
29. Plate KH, Breier G, Farrell CL, Risau W: Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest 67: 529-534, 1992
30. Merzak A, Koochekpour S, Dkhissi F, Raynal S, Lawrence D, Pilkington GJ: Synergism between growth factors in the control of glioma cell proliferation, migration and invasion in vitro. Int J Oncol 6: 1079-1085, 1995
31. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994
32. Li YJ, Hoang-Xuan K, Delattre JY, Poisson M, Thomas G, Hamelin R: Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 11: 597-600, 1995
33. Henson JW, Schnitker BL, Correa KM, von Deimling A, Fassbender F, Xu HJ, Benedict WF, Yandell DW, Louis DN: The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 36: 714-721, 1994
34. Schulze A, Zerfass K, Spitkovsky D, Henglein B, Jansen-Durr P: Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1. Oncogene 9: 3475-3482, 1994
35. Parry D, Bates S, Mann DJ, Peters G: Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J 14: 503-511, 1995
36. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J: Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375: 503-506, 1995
37. Medema RH, Herrera RE, Lam F, Weinberg RA: Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 92: 6289-6293, 1995
38. Dreyling MH, Bohlander SK, Adeyanju MO, Olopade OI: Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization. Cancer Res 55: 984-988, 1995
39. Moullon T, Samara G, Chung WY, Yuan L, Desai R, Sisti M, Bruce J, Tycko B: MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 146: 613-619, 1995
40. Gomi A, Sakai R, Ogawa S, Shinoda S, Hirai H, Masuzawa T: Frequent loss of the cyclin-dependent kinase-4 inhibitor gene in human gliomas. Jpn J Cancer Res 86: 342-346, 1995
41. He J, Olson JJ, James CD: Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 55: 4833-4836, 1995
42. Sonoda Y, Yoshimoto T, Sekiya T: Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma. Oncogene 11: 2145-2149, 1995
43. Izumoto S, Arita N, Ohnishi T, Hiraga S, Taki T, Hayakawa T: Homozygous deletions of p16INK4A/MTS1 and p15INK4B/MTS2 genes in glioma cells and primary glioma tissues. Cancer Lett 97: 241-247, 1995
44. Ueki K, Ono Y, Henson JW, Efird JT, von-Deimling A, Louis DN: CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56: 150-153, 1996
45. Kyritsis AP, Zhang B, Zhang W, Xiao M, Takeshima H, Bondy ML, Cunningham JE, Levin VA, Bruner J: Mutations of the p16 gene in gliomas. Oncogene 12: 63-67, 1996
46. Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavenee WK, Su-Huang HJ: Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Res 55: 1941-1945, 1995
47. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530, 1995
48. Fueyo J, Gomez-Manzano C, Yung WK, Clayman GL, Liu TJ, Bruner J, Levin VA, Kyritsis AP: Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12: 103-110, 1996
49. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang HJ: Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55: 1351-1354, 1995
50. Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371: 257-261, 1994
51. Reynisdottir I, Polyak K, Iavarone A, Massague J: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 9: 1831-1845, 1995
52. Merzak A, McCrea S, Koochekpour S, Pilkington GJ: Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor 1. Br J Cancer 70: 199-203, 1994
53. Tenan M, Benedetti S, Finocchiaro G: Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas. Biochem Biophys Res Commun 217: 195-202, 1995
54. Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ: Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9: 3375-3378, 1994
55. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH: Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 91: 11045-11049, 1994
56. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, Rollins BJ: Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 55: 505-509, 1995
57. Aagaard L, Lukas J, Bartkova J, Kjerulff AA, Strauss M, Bartek J: Aberrations of p16Ink4 and retinoblasloma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int J Cancer 61: 115-120, 1995
58. Raffel C, Ueki K, Harsh GR 4th, Louis DN: The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor. Neurosurgery 36: 971-974, 1995
59. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP: Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 54: 4299-4303, 1994
60. Reifenberger G, Reifenberger J, Ichimura K, Collins VP: Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site. Cancer Res 55: 731-734, 1995
61. Hunter SB, Abbott K, Varma VA, Olson JJ, Barnett DW, James CD: Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. J Neuropathol Exp Neurol 54: 57-64, 1995
62. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS-3rd, James CD: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 54: 5804-5807, 1994
63. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698, 1995
64. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736-2739, 1993
65. Hainaut P: The tumor suppressor protein p53: a receptor to genotoxic stress that controls cell growth and survival. Curr Opin Oncol 7: 76-82, 1995
66. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A: Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest Jun 95: 2633-2643, 1995
67. Nakasu S, Nakasu Y, Nioka H, Nakajima M, Handa J: bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol Berl 88: 520-526, 1994
68. Alderson LM, Castleberg RL, Harsh GR 4th, Louis DN, Henson JW: Human gliomas with wild-type p53 express bcl-2. Cancer Res 55: 999-1001, 1995
69. Ritland SR, Ganju V, Jenkins RB: Region-specific loss of heteroxygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chromosomes Cancer 12: 277-282, 1995
70. Rasheed BK, Fuller GN, Friedman AH, Bigner BB, Bigner SH: Loss of heterozygosity for 10q loci in human gliomas. Cancer 5: 75-82, 1992
71. Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH: Alterations of the TP53 gene in human gliomas. Cancer Res 54: 1324-1330, 1994
72. Karlbom AE, James CD, Boethius J, Cavenec WK, Collins VP, Nordenskjold M, Larsson C: Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum Genet 92: 169-174, 1993
73. Rasheed BK, McLendon RE, Friedman HS, Friedman AH, Fuchs HE, Bigner DD, Bigner SH: Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 10: 2243-2246, 1995
74. Steek PA, Ligon AH, Cheong P, Yung WK, Pershouse MA: Two tumor suppressive loci on chromosome 10 involved in human glioblastomas. Genes Chromosomes Cancer 12: 255-261, 1995
75. Diedrich U, Lucius J, Bittermann HJ, Schlosser M, Ecken B, Behnke J, Pabst B: Loss of alleles in brain tumours: distribution and correlations with clinical course. J Neurol 242: 707-711, 1995
76. Filmus J, Pollack M, Cairncross JG, Buick RN: Amplified, overexpressed and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. Biochem Biophys Res Commun 131: 207-215, 1985
77. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq M, Whittle N, Waterfield MD, Ulrich A, Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144-147, 1985
78. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelslein B: Increased expression of the epidermal growth factor receptor gene in malignant gliomas in invariably associated with gene amplification. Proc Natl Acad Sci 84: 6899-6903, 1987
79. Zhu A, Schaeffer J, Leslie S, Kolm P, El-Mahdi AM: Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys 34: 809-815, 1996
80. Schrock E, Thiel G, Lozanova T, du-Manoir S, Meffert MC, Jauch A, Speicher MR, Nurnberg P, Vogel S, Janisch W: Comparative genomic hybridization of human malignant gliomas reveals multiple amplification sites and non-random chromosomal gains and losses. Am J Pathol 144: 1203-1218, 1994
81. Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD: Tumor antigens in astrocytic gliomas. Glia 15: 244-256, 1995
82. Wikslrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscalello D, Pegram CN, Reist CJ: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55: 3140-3148, 1995
83. Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, Moscatello DK, Wong AJ, Bigner DD, Zalutsky MR: Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res 55: 4375-4382, 1995
84. Hills D, Rowlinson-Busza G, Gullick WJ: Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody. Int J Cancer 63: 537-543, 1995
85. Lang FF, Miller DC, Koslow M, Newcomb EW: Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81: 427-436, 1994
86. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK: Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54: 649-652, 1994
87. Chozick BS, Weicker ME, Pezzullo JC, Jackson CL, Finkelstein SD, Ambler MW, Epstein MH, Finch PW: Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. Cancer 73: 406-415, 1994
88. Von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestler OD, Seizinger BR: Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 52: 4277-4279, 1992
89. Ransom DT, Ritland SR, Kimmel DW, Moertel CA, Dahl RJ, Scheithauer BW, Kelly PJ, Jenkins RB: Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes Chromosomes Cancer 5: 348-356, 1992
90. Von Deimling A, Nagel J, Bender B, Lenartz D, Schramm J, Louis DN, Wiestler OD: Deletion mapping of chromosome 19 in human gliomas. Int J Cancer 57: 676-680, 1994
91. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145: 1175-1190, 1994
92. Ritland SR, Ganju V, Jenkins RB: Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chromosomes Cancer 12: 277-282, 1995
93. Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Pestana A, Rey JA: Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 64: 207-210, 1995
94. Bello MJ, de Campos JM, Vaquero J, Kusak ME, Sarasa JL, Pestana A, Rey JA: Molecular and cytogenetic analysis of chromosome 9 deletions in 75 malignant gliomas. Genes Chromosomes Cancer 9: 33-41, 1994
95. Bello MJ, Leone PE, Nebreda P, de Campos JM, Kusak ME, Vaquero J, Sarasa JL, Garcia-Miguel P, Queizan A, Hernandez-Moneo JL: Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet 83: 160-164, 1995
96. Hshimoto N, Ichikawa D, Arakawa Y, Date K, Ueda S, Nakagawa Y, Horii A, Nakamura Y, Abe T, Inazawa J: Frequent deletions of material from chromosome arm 1p in oligodendroglial tumors revealed by double-target fluorescence in situ hybridization and microsatellite analysis. Genes Chromosomes Cancer 14: 295-300, 1995
97. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestier OD, von Deimling A: Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54: 91-95, 1995
98. Neumann E, Kalousek DK, Norman MG, Steinbok P, Cochrane DD, Goddard K: Cytogenetic analysis of 109 pediatric central nervous system tumors. Cancer Genet Cytogenet 71: 40-49, 1993
99. Ransom DT, Ritland SR, Kimmel DW, Moertel CA, Dahl RJ, Scheithauer BW, Kelly PJ, Jenkins RB: Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes Chromosomes Cancer 5: 348-356, 1992
100. Bijlsma EK, Voesten AM, Bijleveld EH, Troost D, Westerveld A, Merel P, Thomas G, Hulsebos TJ: Molecular analysis of genetic changes in ependymomas. Genes Chromosomes Cancer 13: 272-277, 1995
101. Vagner-Capodano AM, Gentel JC, Gambarelli D, Pellissier JF, Gouzien M, Lena G, Genitori L, Choux M, Raybaud C: Cytogenetic studies in 45 pediatric brain tumors. Pediatr Hematol Oncol 9: 223-235, 1992
102. Karnes PS, Tran TN, Cui MY, Raffel C, Gilles FH, Barranger JA, Ying KL: Cytogenetic analysis of 39 pediatric central nervous system tumors. Cancer Genet Cytogenet 59: 12-19, 1992
103. Vagner-Capodano AM, Zattara-Cannoni H, Gambarelli D, Gentet JC, Genitori L, Lena G, Graziani N, Raybaud C, Choux M, Grisou F: Detection of i(17q) chromosome by fluorescent in situ hybridization (FISH) with interphase nuclei in medulloblastoma. Cancer Genet Cytogenet 78: 1-6, 1994
104. Fujii Y, Hongo T, Hayashi Y: Chromosome analysis of brain tumors in childhood. Genes Chromosomes Cancer 11: 205-215, 1994
105. Adesina AM, Nalbantoglu J, Cavenee WK: p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res 54: 5649-5651, 1994
106. Jay V, Pienkowska M, Becker L, Zielenska M: Primitive neuroectodermal tumors of the cerebrum and cerebellum: absence of t(11:22) translocation by RT-PCR analysis. Mod Pathol 8: 488-491, 1995
107. Ng HK, Lau KM, Tse JY, Lo KW, Wong JH, Poon WS, Huang DP: Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors. Neurosurgery 37: 764-773, 1995
108. Lekanne-Deprez RH, Riegman PH, van Drunen E, Warringa UL, Groen NA, Stefanko SZ, Koper JW, Avezaat CJ, Mulder PG, Zwarthoff EC: Cytogenctic, molecular genetic and pathological analyses in 126 meningiomas. J Neuropathol Exp Neurol 54: 224-235, 1995
109. Merci P, Haong-Xuan K, Sanson M, Moreau-Aubry A, Bijlsma EK, Lazaro C, Moisan JP, Resche F, Nishisho I, Estivill X: Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer 13: 211-216, 1995
110. Papi L, De Vitis LR, Vitelli F, Ammannati F, Mennonna P, Montali E, Bigozzi U: Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas. Hum Genet 95: 347-351, 1995
111. Akagi K, Kurahashi H, Arita N, Hayakawa T, Monden M, Mori T, Takai S, Nishisho I: Deletion mapping of the long arm of chromosome 22 in human meningiomas. Int J Cancer 60: 178-182, 1995
112. Slave I, MacCollin MM, Dunn M, Jones S, Sutton L, Gusella JF, Biegel JA: Exon scanning for mutations of the NF2 gene in pediatric ependymomas, rhabdoid tumors and meningiomas. Int J Cancer 64: 243-247, 1995
113. Schneider BF, Shashi V, von Kap-herr C, Golden WL: Loss of chromosomes 22 and 14 in the malignant progression of meningiomas. A comparative study of fluorescence in situ hybridization (FISH) and standard cytogenetic analysis. Cancer Genet Cytogenet 85: 101-104, 1995
114. Simon M, von Deimling A, Larson JJ, Wellenreuther R, Kaskel P, Waha A, Warnick RE, Tew JM Jr, Menon AG: Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res 55: 4696-4701, 1995
115. Bello MJ, de Campos JM, Kusak ME, Vaquero J, Sarasa JL, Pestana A, Rey JA: Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer 9: 296-298, 1994
116. Sluyser M: Mutations in the estrogen receptor gene. Hum Mutat 6: 97-103, 1995
117. Corvi R, Amler LC, Savelyeva L, Gehring M, Schwab M: MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells. Proc Natl Acad Sci USA 91: 5523-5527, 1994
118. Corvi R, Savelyeva L, Breit S, Wenzel A, Handgretinger R, Barak J, Oren M, Amler L, Schwab M: Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene 10: 1081-1086, 1995
119. Cheng JM, Hiemslra JL, Schneider SS, Naumova A, Cheung NK, Conn SL, Diller L, Sapienza C, Brodeur GM: Preferential amplification of the paternal allele of the N-myc gene in human neuroblastomas. Nat Genet 4: 191-194, 1993
120. Bello MJ, Leone PE, Nebreda P, de Campos JM, Kusak ME, Vaquero J, Sarasa JL, Garcia-Miguel P, Queizar A, Hernandez-Moneo JL: Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet 83: 160-164, 1995
121. Takeda O, Homma C, Maseki N, Sakurai M, Kanda N, Schwab M, Nakamura Y, Kaneko Y: There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes Chromosomes Cancer 10: 30-39, 1994
122. Caron H, Peter M, van Sluis P, Speleman F, de Kraker J, Laureys G, Michon J, Brugieres L, Voute PA, Westerveld A: Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. Hum Mol Genet 4: 535-539, 1995
123. Caron H, van Sluis P, van Roy N, de Kraker J, Speleman F, Voute PA, Westerveld A, Slater R, Versteeg R: Recurrent 1;17 translocations in human neuroblastoma reveal nonhomologous mitotic recombination during the S/G2 phase as a novel mechanism for loss of heterozygosity. Am J Hum Genet 55: 341-347, 1994
124. Van Roy N, Laureys G, Cheng NC, Willem P, Opdenakker G, Versteeg R, Speleman F: 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromosomes Cancer 10: 103-114, 1994
125. Srivatsan ES, Ying KL, Seeger RC: Deletion of chromosome 11 and of 14q sequences in neuroblastoma. Genes Chromosomes Cancer 7: 32-37, 1993
126. Butti G, Gaetani P, Danova M, Assieti R, Girino M, Riccardi A: Cell kinetic studies of human intracranial tumors. J Neurosurg Sci 33: 47-53, 1989
127. Takahashi JA, Mori H, Fukomoto M, Igarashi K, Jaye M, Oda Y, Kikuchi H, Hatanaka M: Gene expression of fibroblast growth factors in human gliomas and meningiomas: Demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumour tissues. Proc Natl Acad Sci 87: 5710-5714, 1990
128. Takahashi JA, Suzui H, Yasuda K et al.: Gene expression of fibroblast growth factor receptors in the tissues of human gliomas and meningiomas. Biochem Biophys Run 177: 1-7, 1991
129. Takahashi JA, Fukomoto M, Kozai Y et al.: Inhibition of cell growth and tumourigenesis of human glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor. FEBS Lett 228: 65-71, 1991
130. Werner MH, Humphery PA, Bigner DD, Bigner SH: Growth effect of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines. Acta Neuropathol 77: 196-201, 1988
131. Werner MH, Nanney LB, Stoscheck CM, King LE: Localization of immunoreactive epidermal growth factor receptors in human nervous system. J Histochem Cytochem 36: 81-86, 1988
132. Arita N, Hayakawa T, Izumoto S, Taki T, Ohnishi T, Yamamoto H, Bitoh S, Mogami H: Epidermal growth factor receptor in human glioma. J Neurosurgery 70: 916-919, 1989
133. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq M, Whittle N, Waterfield MD, Ulrich A, Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144-147, 1985
134. Nister M, Heldin CH, Wasteson A, Wetermark B: A glioma derived analog to platelet-derived growth factor: Demonstration of receptor competing activity and immunological cross-reactivity. Proct Natl Acad Sci USA 81: 926-930, 1984
135. Heldin CH, Westermark B, Wasteson A: Specific receptor for platelet-derived growth factor on cells from connective tissue and glia. Proc Natl Acad Sci 78: 3664-3668, 1981
136. Nister M, Heldin CH, Westermark B: Clonal variation in the production of a platelet-derived growth factor protein and expression of corresponding receptors in a human malignant glioma. Cancer Res 46: 332-340, 1988
137. Jennings MT, Maciunas RJ, Carver R, Bascom CC, Juneau P, Misulis K, Moses HL: TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis. Int J Cancer 49: 129-139, 1991
138. Constam DB, Philipp J, Malipiero UV, ten-Diike P, Schashner M, Fontana A: Differential expression of transforming growth factor-β1, -β2 and -β3 by glioblastoma cells, astrocytes and microglia. J Immunol 148: 1404-1410, 1992
139. Olofsson A, Miyazono K, Kanzaki T, Colosetti P, Engstrom U, Heldin CH: Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large lalent complexes. J Biol Chem 267: 19482-19488, 1992
140. Ruffin PA, Rivoltini L, Silvani A, Boiardi A, Parmiani G: Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother 36: 409-416, 1993
141. Tada T, Yabu K, Kobayashi S: Detection of active form of transforming growth factor-beta in cerebrospinal fluid of patients with glioma. Jpn J Cancer Res 84: 544-548, 1993
142. Huber D, Fontana A, Bodmer S: Activation of human platelet-derived latent transforming growth factor-beta 1 by human glioblastoma cells. Comparison with proteolytic and glycosidic enzymes. Biochem J 277: 165-173, 1991
143. Koochekpour S, Pilkington GJ, Merzak A (Submitted): Expression of Transforming growth factor β isoforms and type II receptor in human gliomas: evidence of an autocrine mechanism in glioma progression in vivo.
144. Jachimczak P, Maciunas RJ, Carver R, Bascom CC, Juneau P, Misulis K, Moses HL: TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis. J Neurosurg 78: 944-951, 1993
145. Merzak A, McCrea S, Koochekpour S, Pilkington GJ: Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor beta-1. Br J Cancer 70: 199-203, 1994
146. Merzak A, Koochekpour S, McCrea S, Roxanis I, Pilkington GJ: Gangliosides modulate proliferation, migration, and invasion of human brain tumour cells in vitro. Mol Chem Neuropathol 24: 121-135, 1995
147. Nakamura O, Ishihara I, Iwamori M, Nagai T, Matsutani M, Nomura K, Takakura K: Lipid composition of human malignant brain tumors. No To Shinkei 39: 221-226, 1987
148. Fredman P, von Holst H, Collins VP, Delheden B, Svennerholm L: Expression of GD3 and 3′-iso LM1 in autopsy brain tumours from patients with malignant tumors. J Neurochem 60: 99-105, 1993
149. Bremer EG, Hansson G, Jansson S, Ericson LE, Nilsson M: Ganglioside-mediated modulation of cell growth: specific effects of GM3 on thyrosine phosphorylation of the epidermal growth factor receptor. J Biol Chem 261: 2434-2440, 1986
150. Van Brocklyn J, Bremer EG, Yates AJ: Gangliosides inhibit platelet-derived growth factor-stimulated receptor dimerization in human glioma. J Neurochem 61: 371-374, 1993
151. Pilkington GJ: Tumour cell migration in the central nervous system. Brain Pathology 4: 157-166, 1994
152. Liotta LA: Tumor invasion and metastases: Role of the extracellular matrix (Rhodes Memorial Award lecture). Cancer Res 46: 1-7, 1986
153. Hart IR, Saini A: Biology of tumour metastasis. Lancet 339: 1453-1457, 1992
154. Yamada KM: Cell surface interactions with extracellular material. Ann Rev Biochem 52: 761-799, 1983
155. Yamada KM, Akiyama SK, Hasegawa T, Hasegawa E, Humphries MJ, Kennedy DW, Nagata K, Urushihara H, Olden K, Chen WT: Recent advances in research on fibronectin and other cell attachment proteins. J Cell Biochem 28: 79-97, 1985
156. Rutka TJ, Apodaca G, Stern R, Rosenblum M: The extracellular matrix of the central and peripheral nervous systems: structure and function. J Neurosurg 69: 155-170, 1988
157. Peters A, Palay SL, Webster H de F: The fine structure of the nervous system: Neurons and their supporting cells, Ed 3. New York, Oxford University Press, 1991
158. Kepes JJ, Rubinstein LJ, Eng LJ: Pleomorphic xanthoastrocytoma: a distinctive meningocerebral glioma of young subjects with relatively favorable prognosis. A study of 12 cases. Cancer 44: 1839-1852, 1979
159. Paulus W, Roggendorf W, Schuppan D: Immunohistochemical investigation of collagen subtypes in human glioblastomas. Virchows Arch Pathol Anat 413: 325-332, 1988
160. Paulus W, Schloe W, Perentes E, Jacobi G, Warmuth-Metz M, Roggendorf W: Desmoplastic supratentorial neuroepithelial tumors of infancy. Histopathology 21: 43-49, 1992
161. Kakita A, Wakabayashi K, Takahashi H, Ohama E, Ikuta F, Tokiguchi S: Primary leptomeningeal glioma: Ultrastructural and laminin immunohistochemical studies. Acta Neuropathol 83: 538-542, 1992
162. McKeever PE, Fligiel SEG, Varani J, Castle RL, Hood TW: Products of cells cultured from gliomas. VII. Extracellular matrix proteins of gliomas which contain glial fibrillary acidic proteins. Lab Invest 60: 286-295, 1989
163. Merzak A, Koochekpour S, Pilkington GJ: Adhesion of human glioma cell
164. Koochekpour S, Merzak A, Pilkington GJ: Extracellular matrix proteins inhibit proliferation, upregulale migration, and induce morphological changes in human glioma cell lines. European J Cancer 31: 375-380, 1995
165. Schiffer D, Cavalla P, Pilkington GJ: Proliferative properties of malignant brain tumours. In: Mikkelsen T, Bjerkvig R, Laerum O-D, Rosenblum ML (eds) Brain Tumor Invasion: Biological, Clinical and Therapeutic Considerations. John Wiley and Sons Inc, in press
166. Pilkington GJ: The role of the extracellular matrix in neoplaslic glial invasion of the nervous system. Brazilian Journal of Medical and Biological Research 29: 1159-1172, 1996
167. Schiffer D, Cavalla P, Chio A, Giordana MT, Marino S, Mauro A, Migheli A: Tumor cell proliferation and apoptosis in medulloblastoma. Acta Neuropathologica 87: 326-370, 1994
168. Pilkington GJ: Glioma heterogeneity in vitro: the significance of growth factors and gangliosides. Neuropath Appl Neurobiol 18: 434-442, 1992
169. Merzak A, Koochekpour S, Pilkinglon GJ: Cell surface gangliosides are involved in the control of human glioma cell invasion in vitro. Neurosci letters 177: 44-46, 1994
170. Koochekpour S, Merzak A, Pilkington GJ: Growth factors and gangliosides stimulate laminin production by human glioma cells in vitro. Neurosci Lett 186: 53-56, 1995
171. Mugnai G, Barletta E, Mannini A: Modulation of the integrin-mediated cell adhesion by complex gangliosides. Trends in Glycoscience and Glycotechnology 6: 199-214, 1994
172. Thompson LK, Horowitz PM, Bentley KL, Thomas DD, Alderete JF, Klebe RJ: Localisation of ganglioside binding site on fibronectin. J Biol Chem 261: 5209-5214, 1986
173. Maidment SL, Merzak A, Koochekpour S, Rooprai HK, Rucklidge GJ, Pilkington GJ: The effect of exogenous gangliosides on matrix metalloproteinase secretion by human glioma cells in vitro. Europ J Cancer 32A: 868-871, 1996
174. Lund-Johansen M, Bjerkvig R, Humphrey PA, Bigner SH, Bigner DD, Laerum OD: Effect of epidermal growth lactor on glioma cell growth, migration and invasion in vitro. Cancer Res 50: 6039-6044, 1990
175. Lund-Johansen M, Forsberg K, Bjerkvig R, Laerum OD: Effects of growth factors on a human glioma cell line during invasion into rat brain aggregates in culture. Acta Neuropathol 84: 190-197, 1992
176. Pilkington GJ, Dunan JR, Rogers JP, Clarke TM, Krott JCA: Growth factor modulation of surface ganglioside expression in cloned neoplastic glia. Neurose Letts 149: 1-5, 1993
177. Salo T, Lyons JG, Rahemtulla F, Birkendal-Hansen H, Larjava H: Transforming growth factor β-1 upregulates type IV collagenase expression in cultured human keratinocytes. J Biol Chem 226: 11436-11441, 1991
178. Overall CM, Wrana JL, Sodek J: Transcriplional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor β-1 in human fibroblasts. J Biol Chem 226: 14064-14071, 1991
179. Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta LA: Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 265: 13933-13938, 1990
180. Liotta LA, Stetler-Stevenson WG: Metalloproteinases and cancer invasion. Seminars in Cancer Biology 1: 99-106, 1990
181. Apodaca G, Rutka JT, Bouhana K, Berens ME, Giblin JR, Rosenblum ML, McKerrow JH, Banda MJ: Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 50: 2322-2329, 1990
182. Rossi M, Rooprai HK, Maidment SL, Rucklidge GJ, Pilkington GJ: Matrix metalloproteinase secretion by cultured glioma cells: influence of serial passaging. Anticancer Res 16: 121-128, 1996
183. Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 83: 298-307, 1995
184. Bindal AK, Hammoud M, Shi WM, Wu SZ, Sawaya R, Rao JS: Prognostic significance of proteolytic enzymes in human brain tumors. J Neurooncol 22: 101-110, 1994
185. Rao JS, Yamamoto M, Mohaman S, Gokaslan ZL, Fuller GN, Stetler-Stevenson WG, Rao VH, Liotta LA, Nicolson GL, Sawaya RE: Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis 14: 12-18, 1996
186. Sawaya RE, Yamamoto M, Gokaslan ZL, Wang SW, Mohanam S, Fuller GN, McCutcheon IE, Steller-Stevenson WG, Nicolson GL, Rao JS: Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp Metastasis 14: 35-12, 1996
187. Halaka AN, Bunning RAD, Bird CC, Gibson M, Reynolds JJ: Production of collagenase and inhibitor by intracranial tumors and dura in vitro. J Neurosurg 59: 461-466, 1983
188. Merzak A, Parker C, Koochekpour S, Sherbert G, Pilkington GJ: Overexpression of the 18A2/mts1 gene and down regulation of the TIMP-2 gene in invasive human glioma cell lines in vitro. Neuropath Appl Neurobiol 20: 614-619, 1994
189. Mignatti P, Robbins E, Rifkin DB: Tumor invasion through the amniotic membrane requirement tor a proteinase cascade. Cell 47: 487-498, 1986
190. Quax PHA, van Muijen GNP, Weening-Verhoeff EJD, Lund LR, Dano K, Ruitner DJ, Verheijen JH: Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator. Its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol 115: 191-199, 1991
191. Laurent TC, Fraser JRE: Hyaluronan. FASEB J 6: 2397-2404, 1992
192. Knudson W, Biswas C, Li Xiao-Qiang, Nemec ER, Toole PB: The role and regulation of tumour-associated hyaluronan. In: Evered D, Whelan J (eds) The Biology of Hyaluronan, Ciba Foundation Symposium 143, pp 150-169. Chichester: Wiley Press, 1989
193. Zigmund SH: Cell locomotion and chemotaxis. Curr Opin Cell Biol 1: 80-86, 1989
194. Steck PA, Moser RP, Bruner JM, Liang L, Freidman AN, Hwang TL, Yung WK: Altered expression and distribution of heparan sulfate proteoglycans in human gliomas. Cancer Res 49: 2096-2103, 1989
195. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B: CD44 is the principal cell surface receptor for hyaluronate. Cell 61: 1303-1313, 1990
196. Goldstein LA, Butcher EC: Identification of mRNA that encodes an alternative form of H-CAM (CD44) in lymphoid and nonlymphoid tissues. Immunogenetics 32: 389-397, 1990
197. Stamenkovic I, Aruffo A, Amiot M, Seed B: The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different potential for hyaluronate-bearing cells. EMBO J 10: 343-348, 1991
198. Brown TA, Bouchard T, St John T, Wayner E, Carter WG: Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons. J Cell Biol 113: 207-221, 1991
199. Stamenkovic I, Amiot M, Pesando JM, Seed B: A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 56: 1057-1062, 1989
200. Quackenbush EJ, Vera S, Greaves A, Letarte M: Confirmation by peptide sequence and co-expression on various cell types of the identity of CD44 and p85 glycoprotein. Mol Immunol 27: 947-955, 1990
201. Gunthert U, Hoffmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cells 65: 13-24, 1991
202. Hofmann M, Rudy W, Zoller M, Tolg C, Ponta H, Herrlich P, Gunthert U: CD44 splice variant confer metastatic behaviour in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 51: 5292-5297, 1991
203. Girgrah N, Ackerley CA, Muscarello MA: Localization of CD44 (P80) on the external surface of a human astrocytoma cell. Neuroreport 2: 441-444, 1991
204. Asher R, Bignami A: Hyaluronate binding and CD44 expression in human glioblastoma cells and astrocytes. Exp Cell Res 203: 80-90, 1992
205. Kuppner MC, Van Meir EG, Gauthier T, Hamou MF, de Tribolet N: Differential expression of the CD44 molecule in human brain tumours. Int J Cancer 50: 572-577, 1992
206. Pilkington GJ, Akinwunmi J, Ognjenovic N, Rogers JP: Differential binding of CD44 on human gliomas in vitro. Neuroreport 4: 259-262, 1993
207. Ariza A, Lopez D, Mate JL, Isamat M, Musulen E, Pugol M, Ley A, Navas-Palacios JJ: The role of CD44 in the invasiveness of glioblastoma multiforme and the noninvasiveness of meningioma: an immunohistochemical study. Hum Pathol 26: 1144-1147, 1995
208. Li H, Hamou MF, de Tribolet N, Jaufeerally R, Hofmann M, Diserens AC, Van Meir EG: Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas. Cancer Res 53: 5345-5349, 1993
209. Kaaijk P, Troost D, Morsink F, Rechnen RMJ, Leenstra S, Bosch DA, Pals ST: Expression of CD44 splice variants in human primary brain tumors. J Neuro-oncol, 1995
210. Culty M, Miyake K, Kincaide PW, Silorski E, Butcher E, Underhill C: The hyaluronate receptor is a member of the CD44 (H-CAM) family of cell surface glycoproteins. J Cell Biol 111: 2765-2774, 1990
211. Miyake K, Underhill CB, Lesley J, Kinkade PW: Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J Exp Med 172: 69-75, 1990
212. Sy MS, Guo YJ, Stamenkovic I: Distinct effects of two CD44 isoforms on tumour growth in vivo. J Exp Med 174: 859-866, 1991
213. Merzak A, Koochekpour S, Pilkington GJ: CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer Res 54: 3988-3992, 1994
214. Okada H, Yoshida J, Sokabe M, Wakabayashi T, Hagiwara M: Suppression of CD44 expression decreases migration and invasion of human glioma cells. Int J Cancer 66: 255-260, 1996
215. Koochekpour S, Pilkington GJ, Merzak A: Hyaluronic acid/CD44H interaction induces cell detachment and stimulates migration and invasion of human glioma cells in vitro. Int J Cancer 63: 450-454, 1995
216. Takeichi M: The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development 102: 639-655, 1988
217. Takeichi M: Cadherin cell adhesion receptors as a morphogenic regulator. Science 251: 1451-1455, 1991
218. Doki Y, Shiozaki H, Tahara H, Inoue M, OkIihara K, Kadowaki T, Takeishi M, Mori T: Correlation between E-cadherin expression and invasiveness in vitro in a human esophageal cancer cell line. Cancer Res 53: 3421-3426, 1993
219. Fahraeus R, Chen W, Trivedi P, Klein G, Öbrink B: Decreased expression of E-cadherin and increased invasive capacity in EBV-LMP transfected human epithelial and murine adenocarcinoma cells. Int J Cancer 52: 834-838, 1992
220. Filmus J, Pollack M, Cairncross JG, Buick RN: Amplified, overexpressed and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. Biochem Biophys Res Commun 131: 207-215, 1985
221. Schipper JH, Frixen UH, Behrens J, Unger A, Jahnke K, Birchmeier W: E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumour differentiation und lymph node metastasis. Cancer Res 51: 6328-6337, 1991
222. Mayer B, Johnson JP, Leitl F, Jauch KW, Heiss MM, Schildberg KW, Birchmeier W, Funke I: E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 53: 1690-1695, 1993
223. Shiozaki H, Tahara H, Oka H, Miyata M, Kobayashi K, Tamura S, Iihara K, Doki Y, Hirano S, Takeishi M, Mori T: Expression of immuno-reactive E-cadherin adhesion molecules in human cancers. Am J Pathol 139: 17-23, 1991
224. Behrens J, Mareel MM, Van Roy FM, Birchmeier W: Dissecting tumour cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 108: 2435-2447, 1989b
225. Frixen UH, Behrens J, Sacks M, Eberle G, Voss B, Warda A, Löchner D, Birchmeier W: E-cadherin mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113: 173-185, 1991
226. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, Van Roy F: Genetic manipulation of E-cadherin expression by epithelial tumour cells reveals an invasion suppressor role. Cell: 66: 107-119, 1991
227. Koochekpour S, Pierce E, Doshi R, Pilkington GJ, Merzak A (Submitted): E-cadherin expression is correlated to nalignancy but inversely correlated to infiltrative invasiveness of gliomas in vivo and in vitro
228. Plate KH: Gene therapy of malignant glioma via inhibition of tumor angiogenesis. Cancer Met Reviews (in press)
229. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990
230. Folkman J, Shing Y: Angiogenesis. J Biol Chem 267: 10931-10934, 1992
231. Folkman J, Merler E, Abernathy C, Williams G: Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133: 275-288, 1971
232. Folkman J, Klagsbrun M: Angiogenic factors. Science 235: 442-447, 1987
233. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 6398: 845-848, 1992
234. Alvarez JA, Baird A, Tatum J, Daucher R, Chorsky A, Gonzalez AM, Stopa EG: Localization of basic fibroblast growth factor and vascular endothelial growth factor in human glial neoplasms. Modern pathol 5: 303-307, 1992
235. Berkman RA, Merrill MJ, Reihold WC, Monacci WT, Saxena A, Clark WC, Ali IU, Oldfield EH: Expression of vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91: 153-159, 1993
236. Koochekpour S, Bullock P, Dean A, Pilkington GJ, Merzak A: Expression of vascular endothelial growth factor in the cyst fluid of human cerebral gliomas. Oncology Reports 2: 1147-1149, 1995
237. Sioussat TM, Dvorak HF, Brock TA, Senger DR: Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies. Arch Biochem Biophys 301: 15-20, 1993
238. Koochekpour S, Merzak A, Pilkington GJ: Vascular endothelial growth factor production is stimulated in response to growth factors in human glioma cells. Oncology Reports 2: 1059-1061, 1995
239. Koochekpour S, Merzak A, Pilkington GJ: Vascular endothelial growth factor production is stimulated by TGF-β isoforms in human glioma cells in vitro. Cancer Letts 102: 209-215, 1996, 1995
240. Ziche M, Morbidelli L, Alessandri J, Gullino PM: Angiogenesis can be stimulated or repressed in vivo by a change in GM3:GD3 ganglioside ratio. Lab Invest 67: 711-715, 1992
241. Takeshima F, Iwasaki K, Shimokava I, Ikeda T, Matsuo T: Immunohistochemical localisation of gangliosides in ENU-induced rat glioma. Acta Pathol Jpn 42: 558-565, 1992
242. Nakamura O, Iwamori M, Matsutani M, Takakura K: Ganglioside GD3 shedding by human gliomas. Acta Neurochir Wien 109: 34-36, 1991
243. Koochekpour S, Pilkington GJ: Vascular and perivascular GD3 expression in human glioma. Cancer Letts 104: 97-102, 1996
244. Fine HA: Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. Neurol-Clin 13: 827-846, 1995
245. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552, 1992
246. Takamiya Y, Short MP, Moolten FL, Fleet C, Mineta T, Breakefield XO, Martuza RL: An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg 79: 104-110, 1993
247. Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SL: Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 91: 3054-3057, 1994
248. Pcrez-Cruet MJ, Trask TW, Chen SH, Goodman JC, Woo SL, Grossman RG, Shine HD: Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res 39: 506-511, 1994
249. Walther W, Stein U, Pfeil D: Gene transfer of human TNF alpha into glioblastoma cells permits modulation of mdr 1 expression and potentiation of chemosensitivity. Int J Cancer 61: 832-839, 1995
250. Glick RP, Lichtor T, Kim TS, Ilangovan S, Cohen EP: Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo. Neurosurgery 36: 548-555, 1995
251. Wei MX, Tamiya T, Hurford RK Jr, Boviatsis EJ, Tepper RI, Chiocca EA: Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ ret gene transfer. Hum Gene Ther 6: 437-443, 1995
252. Yamanaka R, Tanaka R, Yoshida S, Saitoh T, Fujita K: Growth inhibition of human glioma cells modulated by retrovirus gene transfection with antisense IL-8. J Neurooncol 25: 59-65, 1995
253. Weller M, Malipiero U, Rensing Ehl A, Barr PJ, Fontana A: Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 55: 2936-2944, 1995
254. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative FLK-1 mutant. Nature 367: 576-579, 1994
255. Pilkington GJ, Lantos PL: Pathology of Experimental Brain Tumours. In: Thomas DGT (ed.) 'Neurooncology, Primary Malignant Brain Tumours'. Edward Arnold Chapter 4, pp 51-76, 1990